CXCR3 ligand–modulating protein inhibitors, (EMP3 inhibitor and GSK126 [EZH2 inhibitor]) combined with anti-PD-1 leads to increased CXCR3 ligand secretion to recruit T cells to magnify the anti-PD-1 effects, thus arresting GBM growth and prolonging survival. The gene discussed is EMP3; the disease is glioblastoma.